Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective.
The objective of this systematic review and meta‐analysis was to evaluate the validity of progression‐free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane C...
Russell Leong, David Chen, Laith Almasri et al.· Cancer· 0 citations
BACKGROUND
Immune checkpoint inhibitors (ICIs) added to chemotherapy are established in solid tumors, but most trials enroll patients with ECOG performance status (PS) 0-1 patients. Whether baseline PS modifies the relative benefit of adding an ICI has not been formally tested using a within-trial interaction analysis....
Wafa Ali Asaad, Salah Ameen Abdu, Yue-Ying Zhou et al.· Critical reviews in oncology...· 0 citations
Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.
Si-Yu Sun, Jun-Hao Zhang, Yan Li et al.· Frontiers in Immunology· 0 citations
Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...
J. Dai, Meng-Ni Liu, Hu Li et al.· Frontiers in Pharmacology· 0 citations
Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...
A. Sherry, N. Meimoun, A. Miller et al.· The Oncologist· 0 citations
Background Optimal second-line systemic therapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study compared the efficacy and safety of available second-line treatments after tyrosine kinase inhibitor (TKI) failure and explored treatment strategies after immune checkpoint inhibitor (ICI) exposure....
Xin-Ming Li, Gui-Lin Nie, Yao-Qun Wang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.